AIM ImmunoTech (AIM) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pluri is the larger company by market cap ($12.6 million vs $7.2 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AIM | PLUR |
|---|---|---|
| Share price | $0.1796 | $1.00 |
| Market cap | $7.17M | $12.61M |
| 1-day change | -1.75% | -3.85% |
| YTD return | — | -66.56% |
| 1-year return | — | -75.49% |
| 5-year return | — | -95.23% |
| EPS (TTM) | $-3.03 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.79 | $4.87 |
| 52-week low | $0.17 | $0.85 |
| Distance from 52-week high | -93.57% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +2266.37% | — |
| Average volume | 4.70M | 24.97K |
| Shares outstanding | 39.89M | 12.61M |
| Employees | 19 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AIM ImmunoTech
AIM stock →AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
Healthcare · Biotechnology · 19 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
AIM vs PLUR FAQ
Which is bigger, AIM ImmunoTech or Pluri?
Pluri (PLUR) is larger, with a market capitalization of $12.61M compared with $7.17M for AIM ImmunoTech (AIM).
Are AIM ImmunoTech and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.